AJMC articleshttps://www.ajmc.com/newsAJMC articles© 2026 MJH Life Sciences™ and AJMC. All rights reserved.Sat, 31 Oct 2026 09:58:14 +00005en-us14447https://www.ajmc.com/newshttps://www.ajmc.com/logo.webphttps://www.ajmc.com/view/the-next-decade-of-cancer-care-is-coming-home-who-will-be-in-the-driver-s-seat-https://www.ajmc.com/view/the-next-decade-of-cancer-care-is-coming-home-who-will-be-in-the-driver-s-seat-<![CDATA[Home-based oncology transforms practice transformation with clear bagging, protecting Medicare reimbursement, provider control, and lower costs for patients, health systems, and payers.]]>Sat, 31 Oct 2026 06:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/disability-economic-toll-of-multimorbidity-climb-in-older-adultshttps://www.ajmc.com/view/disability-economic-toll-of-multimorbidity-climb-in-older-adults<![CDATA[Costs of multimorbidity in older adults are climbing faster than its disability toll, and study authors say policy should look past single-disease programs.]]>Fri, 30 Oct 2026 20:17:32 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/october-fda-approvals-bring-advances-across-5-specialtieshttps://www.ajmc.com/view/october-fda-approvals-bring-advances-across-5-specialties<![CDATA[October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties. ]]>Fri, 30 Oct 2026 20:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/faq-pbm-reform-340b-and-medicare-shifts-payers-face-in-2027https://www.ajmc.com/view/faq-pbm-reform-340b-and-medicare-shifts-payers-face-in-2027<![CDATA[PBM reform, Medicare Advantage exits, and the 340B rebate pilot are reshaping drug access. Here is what payers need to know heading into 2027.]]>Fri, 30 Oct 2026 19:48:42 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/bronchiectasis-is-underrecognized-obada-shamaa-md-phdhttps://www.ajmc.com/view/bronchiectasis-is-underrecognized-obada-shamaa-md-phd<![CDATA[UChicago Medicine’s Obada Shamaa, MD, PhD, discusses why bronchiectasis is underrecognized and how to personalize airway clearance and antibiotic plans.]]>Fri, 30 Oct 2026 18:51:06 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/evidence-based-treatment-guidelines-and-advances-in-therapeutic-agentshttps://www.ajmc.com/view/evidence-based-treatment-guidelines-and-advances-in-therapeutic-agents<![CDATA[Treatment of DMD has evolved from supportive multidisciplinary care to multimodal disease-modifying treatment, including therapies that target the underlying molecular defect.]]>Fri, 30 Oct 2026 18:48:49 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/duchenne-muscular-dystrophy-understanding-pathophysiology-and-disease-burdenhttps://www.ajmc.com/view/duchenne-muscular-dystrophy-understanding-pathophysiology-and-disease-burden<![CDATA[Duchenne muscular dystrophy (DMD) is a rare neuromuscular disease that continues to result in progressive loss of ambulation, respiratory failure, cardiomyopathy, and early mortality.]]>Fri, 30 Oct 2026 18:48:49 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/managed-care-strategies-and-considerationshttps://www.ajmc.com/view/managed-care-strategies-and-considerations<![CDATA[DMD is associated with a substantial and progressively increasing economic burden.]]>Fri, 30 Oct 2026 18:48:49 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/bispecific-program-design-varies-by-practice-size-experts-sayhttps://www.ajmc.com/view/bispecific-program-design-varies-by-practice-size-experts-say<![CDATA[Bispecific programs differ by practice size, but shared core components can guide adaptation, experts said at a webinar for the Bispecifics Network.]]>Fri, 30 Oct 2026 16:40:23 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/shortening-the-road-to-a-bipolar-diagnosis-justin-t-ray-pmhnp-bchttps://www.ajmc.com/view/shortening-the-road-to-a-bipolar-diagnosis-justin-t-ray-pmhnp-bc<![CDATA[Bipolar disorder often goes undiagnosed for years, and clinicians need to separate mood episodes from normal emotions and keep patients on treatment.]]>Fri, 30 Oct 2026 16:37:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/vibegron-persistence-near-60-at-1-year-in-real-world-oab-studyhttps://www.ajmc.com/view/vibegron-persistence-near-60-at-1-year-in-real-world-oab-study<![CDATA[A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.]]>Fri, 30 Oct 2026 16:28:38 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/machine-learning-models-flag-nonobese-masld-using-routine-blood-testshttps://www.ajmc.com/view/machine-learning-models-flag-nonobese-masld-using-routine-blood-tests<![CDATA[Two machine learning models identifies MASLD in lean adults using 8 routine clinical measurements.]]>Fri, 30 Oct 2026 16:16:22 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/pharmacists-take-on-education-and-toxicity-triage-in-bispecific-carehttps://www.ajmc.com/view/pharmacists-take-on-education-and-toxicity-triage-in-bispecific-care<![CDATA[Pharmacists are moving beyond order verification into patient education, adverse effect mitigation, and parts of toxicity triage in bispecific care.]]>Fri, 30 Oct 2026 15:16:57 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/weekly-gefurulimab-improves-daily-function-in-generalized-mghttps://www.ajmc.com/view/weekly-gefurulimab-improves-daily-function-in-generalized-mg<![CDATA[Weekly gefurulimab cut MG-ADL scores by 4.2 points vs 2.6 with placebo at week 26 in adults with generalized myasthenia gravis in the PREVAIL study. ]]>Fri, 30 Oct 2026 14:38:57 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/small-studies-show-high-upadacitinib-response-in-alopecia-areatahttps://www.ajmc.com/view/small-studies-show-high-upadacitinib-response-in-alopecia-areata<![CDATA[Meta-analysis suggests off-label upadacitinib drives major alopecia areata hair regrowth and SALT score gains, but phase 3 trials show lower responses.]]>Fri, 30 Oct 2026 14:20:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/kidney-week-2026-recap-igan-advances-value-based-care-ckd-care-gapshttps://www.ajmc.com/view/kidney-week-2026-recap-igan-advances-value-based-care-ckd-care-gaps<![CDATA[Kidney Week 2026 brought strong IgAN data, looked back on 5 years of value-based kidney care, and highlighted evidence of persistent CKD care gaps. ]]>Fri, 30 Oct 2026 13:24:02 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/bispecific-intensification-yields-73-mrd-negative-cr-rate-in-high-risk-newly-diagnosed-myelomahttps://www.ajmc.com/view/bispecific-intensification-yields-73-mrd-negative-cr-rate-in-high-risk-newly-diagnosed-myeloma<![CDATA[Primary end point results from the phase 2 GEM-TECTAL trial, presented at IMS 2026 in Glasgow, Scotland, support further study of a transplant-free, bispecific-based frontline strategy for patients with the hardest-to-treat disease.]]>Fri, 30 Oct 2026 12:07:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/ms-progression-explained-relapse-associated-worsening-vs-pirahttps://www.ajmc.com/view/ms-progression-explained-relapse-associated-worsening-vs-pira<![CDATA[Disability in MS accrues through two distinct biological engines. Recognizing relapse-independent progression changes how clinicians assess patients and how they build trust with those who feel worse despite stable MRI.]]>Fri, 30 Oct 2026 12:05:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/selecting-first-line-therapy-in-egfr-exon-20-nsclc-toxicity-and-monitoringhttps://www.ajmc.com/view/selecting-first-line-therapy-in-egfr-exon-20-nsclc-toxicity-and-monitoring<![CDATA[Efficacy sets the starting point, but performance status, comorbidities, patient priorities, and distinct adverse event patterns determine which first-line regimen a patient actually receives.]]>Fri, 30 Oct 2026 12:05:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/how-bronchiectasis-feels-symptoms-and-daily-patient-burdenhttps://www.ajmc.com/view/how-bronchiectasis-feels-symptoms-and-daily-patient-burden<![CDATA[Behind every case of bronchiectasis is a self-perpetuating cycle of cough, breathlessness, and infection that leaves many patients unable to return to their prior baseline health.]]>Fri, 30 Oct 2026 12:05:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/bronchiectasis-explained-pathophysiology-prevalence-and-evolving-modelshttps://www.ajmc.com/view/bronchiectasis-explained-pathophysiology-prevalence-and-evolving-models<![CDATA[Bronchiectasis pathophysiology looks less linear and more dynamic than once believed, and its true prevalence appears far higher than commonly assumed across the adult population.]]>Fri, 30 Oct 2026 12:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/ms-epidemiology-who-is-affected-and-where-unmet-need-remainshttps://www.ajmc.com/view/ms-epidemiology-who-is-affected-and-where-unmet-need-remains<![CDATA[MS prevalence continues to rise and the demographic profile is broader than long assumed. The panel identifies progressive biology as the largest remaining unmet need in the disease.]]>Fri, 30 Oct 2026 12:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/egfr-exon-20-insertion-nsclc-prevalence-testing-and-standard-of-carehttps://www.ajmc.com/view/egfr-exon-20-insertion-nsclc-prevalence-testing-and-standard-of-care<![CDATA[A rare EGFR subtype demands comprehensive molecular testing at diagnosis, and the first-line standard has shifted from chemotherapy alone to a targeted combination with survival benefit.]]>Fri, 30 Oct 2026 12:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/precision-medicine-adoption-hindered-by-coverage-education-gapshttps://www.ajmc.com/view/precision-medicine-adoption-hindered-by-coverage-education-gaps<![CDATA[Pamala A. Pawloski, PharmD, outlines barriers to precision medicine adoption at AMCP Nexus 2026, calling for standardization and education.]]>Thu, 29 Oct 2026 21:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/logistics-payer-rules-and-care-coordination-shape-access-to-cancer-innovationhttps://www.ajmc.com/view/logistics-payer-rules-and-care-coordination-shape-access-to-cancer-innovation<![CDATA[Oncologists reveal why breakthrough cancer drugs still stall—referral gaps, payer delays, caregiver needs, and pharmacy bottlenecks reshape access across tumor types.]]>Thu, 29 Oct 2026 20:50:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/closing-the-gap-between-new-ckd-therapies-and-patients-who-need-themhttps://www.ajmc.com/view/closing-the-gap-between-new-ckd-therapies-and-patients-who-need-them<![CDATA[Experts at ASN Kidney Week say earlier detection, national CKD screening, and faster uptake are needed to bring new therapies to patients.]]>Thu, 29 Oct 2026 20:01:52 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/right-diagnosis-is-key-to-treating-bipolar-justin-t-ray-pmhnp-bchttps://www.ajmc.com/view/right-diagnosis-is-key-to-treating-bipolar-justin-t-ray-pmhnp-bc<![CDATA[Bipolar disorder can take 5 to 10 years to diagnose, and missing it can harm patients’ jobs, relationships, finances, and health.]]>Thu, 29 Oct 2026 19:57:55 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/elagolix-noninferior-to-dienogest-for-endometriosis-pain-in-phase-3-trialhttps://www.ajmc.com/view/elagolix-noninferior-to-dienogest-for-endometriosis-pain-in-phase-3-trial<![CDATA[Elagolix 150 mg was noninferior to dienogest 2 mg for reducing moderate-to-severe endometriosis pain in a phase 3 trial of 230 women in India.]]>Thu, 29 Oct 2026 19:45:09 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/closing-the-gap-from-hcv-diagnosis-to-cure-norah-terrault-md-mphhttps://www.ajmc.com/view/closing-the-gap-from-hcv-diagnosis-to-cure-norah-terrault-md-mph<![CDATA[Norah Terrault, MD, MPH, on why few diagnosed patients reach HCV cure and how primary care test-and-treat can close the gap.]]>Thu, 29 Oct 2026 19:40:37 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/frontal-fibrosing-alopecia-treatment-largely-similar-in-black-white-patientshttps://www.ajmc.com/view/frontal-fibrosing-alopecia-treatment-largely-similar-in-black-white-patients<![CDATA[Initial frontal fibrosing alopecia treatment was largely similar in Black and White patients, though tetracycline use was higher in Black patients.]]>Thu, 29 Oct 2026 17:45:20 GMTAJMCusAJMC Articles